Compare Stocks: AEON, EVAX, JSPR, and ATNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.28	$0.48	$0.22 ▼ $1.45	$6.96M	0.65	612,276 shs	182,357 shs
ATNM Actinium Pharmaceuticals	$1.04	$0.93	$0.74 ▼ $1.81	$32.70M	0.01	146,795 shs	489,561 shs
EVAX Evaxion A/S	$3.34	$3.18	$2.52 ▼ $12.15	$27.86M	0.29	13,184 shs	19,831 shs
JSPR Jasper Therapeutics	$0.79	$0.59	$0.32 ▼ $3.14	$22.12M	3.02	798,981 shs	567,510 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	0.00%	-0.72%	-6.71%	-67.94%	-64.18%
ATNM Actinium Pharmaceuticals	0.00%	+30.42%	+12.81%	-11.11%	-38.46%
EVAX Evaxion A/S	0.00%	+9.15%	+8.44%	-18.34%	+15.97%
JSPR Jasper Therapeutics	0.00%	+11.36%	-10.72%	-2.03%	-74.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.28	$0.48	$0.22 ▼ $1.45	$6.96M	0.65	612,276 shs	182,357 shs
ATNM Actinium Pharmaceuticals	$1.04	$0.93	$0.74 ▼ $1.81	$32.70M	0.01	146,795 shs	489,561 shs
EVAX Evaxion A/S	$3.34	$3.18	$2.52 ▼ $12.15	$27.86M	0.29	13,184 shs	19,831 shs
JSPR Jasper Therapeutics	$0.79	$0.59	$0.32 ▼ $3.14	$22.12M	3.02	798,981 shs	567,510 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	0.00%	-0.72%	-6.71%	-67.94%	-64.18%
ATNM Actinium Pharmaceuticals	0.00%	+30.42%	+12.81%	-11.11%	-38.46%
EVAX Evaxion A/S	0.00%	+9.15%	+8.44%	-18.34%	+15.97%
JSPR Jasper Therapeutics	0.00%	+11.36%	-10.72%	-2.03%	-74.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	2.75	Moderate Buy	$1.10	299.85% Upside
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	380.77% Upside
EVAX Evaxion A/S	2.67	Moderate Buy	$11.00	229.34% Upside
JSPR Jasper Therapeutics	2.44	Hold	$8.17	933.62% Upside

Current Analyst Ratings Breakdown

Latest AEON, EVAX, JSPR, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	AEON AEON Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00 ➝ $1.20
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
8/12/2026	JSPR Jasper Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$2.00
7/30/2026	AEON AEON Biopharma	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$1.00
7/17/2026	JSPR Jasper Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	EVAX Evaxion A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/11/2026	EVAX Evaxion A/S	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
5/27/2026	AEON AEON Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
ATNM Actinium Pharmaceuticals	$35.09M	0.93	N/A	N/A	$1.31 per share	0.79
EVAX Evaxion A/S	$7.53M	3.70	N/A	N/A	$2.04 per share	1.64
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$4.42	1.53	N/A	N/A	N/A	N/A	-994.63%	N/A
ATNM Actinium Pharmaceuticals	-$48.82M	$0.36	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
EVAX Evaxion A/S	-$7.71M	-$1.47	N/A	0.61	N/A	N/A	-73.56%	-37.45%	N/A
JSPR Jasper Therapeutics	-$75.80M	-$1.59	N/A	N/A	N/A	N/A	-712.13%	-119.00%	N/A

Latest AEON, EVAX, JSPR, and ATNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	JSPR Jasper Therapeutics	-$0.2678	-$0.10	+$0.1678	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVAX Evaxion A/S	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
EVAX Evaxion A/S	0.41	5.85	5.85
JSPR Jasper Therapeutics	N/A	2.26	2.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
ATNM Actinium Pharmaceuticals	27.50%
EVAX Evaxion A/S	11.04%
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	9.40%
ATNM Actinium Pharmaceuticals	0.60%
EVAX Evaxion A/S	41.64%
JSPR Jasper Therapeutics	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	25.30 million	74.37 million	Not Optionable
ATNM Actinium Pharmaceuticals	30	31.44 million	29.32 million	Optionable
EVAX Evaxion A/S	60	8.34 million	4.87 million	No Data
JSPR Jasper Therapeutics	20	28.00 million	27.35 million	Optionable

AEON, EVAX, JSPR, and ATNM Headlines

Recent News About These Companies

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Update

August 16 at 4:21 AM | americanbankingnews.com

Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 15 at 4:36 AM | finanznachrichten.de

Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at Piper Sandler

August 15 at 3:42 AM | americanbankingnews.com

Jasper Therapeutics (NASDAQ:JSPR) Cut to Sell at Wall Street Zen

August 15 at 1:12 AM | americanbankingnews.com

Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidates

August 14 at 3:11 PM | blockonomi.com

Jasper Therapeutics Reports Q2 2026 Results and Completion of Kira Pharmaceuticals Acquisition

August 14 at 11:30 AM | quiverquant.comQ

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 14 at 11:00 AM | globenewswire.com

Jasper Therapeutics (JSPR) Projected to Post Earnings on Wednesday

August 11, 2026 | americanbankingnews.com

JSPR Completes Briquilimab Trial In Chronic Hives, Setting Up Next Risk–Reward Catalyst

August 6, 2026 | tipranks.com

Jasper Therapeutics Halts Briquilimab Extension Study in Chronic Urticaria: What Investors Should Know

August 6, 2026 | tipranks.com

Jasper Therapeutics Completes Kira Acquisition and PIPE Financing

July 19, 2026 | theglobeandmail.com

Jasper Therapeutics, Inc. Announces Merger with Kira Pharmaceuticals

July 17, 2026 | finanznachrichten.de

Jasper Therapeutics Merges With Kira Pharmaceuticals

July 17, 2026 | marketwatch.com

Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition and Announces $132 Million Private Placement and KP-301/KP-402 Out-Licensing to Mirador Therapeutics

July 16, 2026 | quiverquant.comQ

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

July 16, 2026 | globenewswire.com

Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway

July 8, 2026 | theglobeandmail.com

Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

June 3, 2026 | zacks.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Jasper Therapeutics (JSPR) and Corbus Pharmaceuticals (CRBP)

June 2, 2026 | theglobeandmail.com

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

June 1, 2026 | globenewswire.com

Jasper Therapeutics Announces Board Resignation and Committee Change

May 21, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, EVAX, JSPR, and ATNM Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.28 0.00 (0.00%)

Closing price 08/14/2026 03:59 PM Eastern

Extended Trading

$0.28 +0.00 (+1.05%)

As of 08/14/2026 07:40 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Actinium Pharmaceuticals NYSE:ATNM

$1.04 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.02 -0.02 (-2.21%)

As of 08/14/2026 08:00 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Evaxion A/S NASDAQ:EVAX

$3.34 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.37 +0.03 (+0.87%)

As of 08/14/2026 07:57 PM Eastern

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Jasper Therapeutics NASDAQ:JSPR

$0.79 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.75 -0.04 (-4.57%)

As of 08/14/2026 07:46 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AEON, EVAX, JSPR, and ATNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AEON, EVAX, JSPR, and ATNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AEON, EVAX, JSPR, and ATNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, EVAX, JSPR, and ATNM Company Descriptions

AEON Biopharma NASDAQ:AEON

Actinium Pharmaceuticals NYSE:ATNM

Evaxion A/S NASDAQ:EVAX

Jasper Therapeutics NASDAQ:JSPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AEON, EVAX, JSPR, and ATNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AEON, EVAX, JSPR, and ATNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AEON, EVAX, JSPR, and ATNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON, EVAX, JSPR, and ATNM Company Descriptions

AEON Biopharma NASDAQ:AEON

Actinium Pharmaceuticals NYSE:ATNM

Evaxion A/S NASDAQ:EVAX

Jasper Therapeutics NASDAQ:JSPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools